---
title: "JP Morgan maintains BeOne Medicines at Overweight, raises price target to $460 from $445"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306162095.md"
description: "JP Morgan maintained its Overweight rating on BeOne Medicines and raised its price target to $460 from $445. This adjustment implies a 68.3% upside potential based on the November 19 closing price of $273.29. The move aligns with recent analyst sentiment, as other firms like Morgan Stanley and RBC Capital have also issued positive ratings with targets ranging between $446 and $476 over the past month."
datetime: "2026-11-19T18:35:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306162095.md)
  - [en](https://longbridge.com/en/news/306162095.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306162095.md)
generator: "portal-rs"
---

# JP Morgan maintains BeOne Medicines at Overweight, raises price target to $460 from $445

JP Morgan maintained BeOne Medicines at Overweight and raised its price target to $460 from $445, a 3.4% increase.

The price target implies an upside of 68.3% from the Nov 19 close of $273.29.

**Recent analyst actions on BeOne Medicines**

| Date   | Firm              | Action     | Rating            | Price target |
| ------ | ----------------- | ---------- | ----------------- | ------------ |
| Nov 13 | Morgan Stanley    | Maintains  | Overweight        | $476         |
| Nov 6  | RBC Capital       | Maintains  | Outperform        | $465         |
| Nov 6  | Truist Securities | Reiterates | Buy               | $448         |
| Nov 6  | Barclays          | Maintains  | Overweight        | $446         |
| Nov 6  | Citizens          | Maintains  | Market Outperform | $463         |

Across the five most recent analyst notes published on BeOne Medicines over the past 30 days, price targets range from $446 to $476.

Explore more price target data and ratings for BeOne Medicines on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)

## Related News & Research

- [Wells Fargo maintains BeOne Medicines at Overweight, raises price target to $435 from $400](https://longbridge.com/en/news/304659494.md)
- [BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investment](https://longbridge.com/en/news/305810947.md)
- ['Rockets are hard' - yet this analyst thinks AST SpaceMobile's stock is ready to rebound](https://longbridge.com/en/news/306159756.md)
- [Securitize Tokenizes Anthropic Stock Onchain on First Day of Public Trading | ANT Stock News](https://longbridge.com/en/news/306158867.md)
- [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**